Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.80 |
| ▸ | ITGAV | P06756 | 18/20 | 0.80 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.80 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.66 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.66 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418817 | 0.95 | ITGB3 (0.74) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419477 | 0.93 | ITGB3 (0.78) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6423290 | 0.93 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419470 | 0.93 | ITGB3 (0.78) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6418095 | 0.92 | ITGB3 (0.78) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6418086 | 0.92 | ITGB3 (0.78) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419346 | 0.92 | ITGB3 (0.82) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL12010935 | 0.91 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL979390 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL30856550 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | claimed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | claimed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | claimed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | claimed |
| WO-2005124346-A1 | 4-1BB RECEPTORS ARE EXPRESSED ON REGULATORY T-CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGAV 302/4885ITGA2B 191/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGAV 302/4885ITGA2B 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.